FDA approval of a paediatric formulation of dolutegravir brings hope to infants and young children living with HIV around the world
MPP thanks Unitaid for new 5-year grant and acknowledges the key role partners – including originators and generic manufacturers – have played in making affordable quality medicines accessible
Leading Generic Drug Makers Unite to Pledge Capacity for Developing and Delivering Affordable COVID-19 Interventions as Pandemic Intensifies
Algeria gains inclusion to ViiV Healthcare and MPP adult licence enabling greater access to dolutegravir-based HIV treatments
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to June 2020
Billion doses of treatment supplied from January 2012 to June 2020
Million patient-years of treatment through MPP’s generic partners, from January 2012 to June 2020
For Everyone Everywhere
Discover where we helped and what we have achieved
👏MPP thanks new signees @Cipla_Global @drreddys & Jiangxi Dongbang Pharmaceutical for #SUCCESSpledge to pool manufacturing & expertise to bring affordable #COVID19treatments to LMICs. Kudos for your contribution in #LeavingNoOneBehind #JoinThePledge 👉https://t.co/iMZ0UBhNLC https://t.co/r1pykkAKB7
MPP’s ED @CharlieGore: “Young children have been long left behind in the fight against #HIV. They deserve better. This excellent news on the adapted #DTG formulation promises a future to infants living with HIV.” https://t.co/WtUm1LgDDA @CHAI_health @ViatrisInc @ViiVHC @Unitaid https://t.co/Y3fiNCMfn0
👏👏MPP congratulates our licensee @ViatrisInc (formerly @MylanNews) for the @US_FDA approval of #paediatric #DTG 10mg. The announcement brings hope for infants & young children living with #HIV around the 🌍 @CHAI_health @ViiVHC @Unitaid Read more 👉 https://t.co/WtUm1LgDDA https://t.co/LAmkjK0XdJ
🗞️The latest update of #MedsPaL is out. Scan through the database's new content and functionalities: ✅ latest inclusion of #COVID19, #HIV, #TB products & more! ✅ new filter by disease area, including #COVID19 and more! 👉https://t.co/r5PuvXFm0E https://t.co/ys7FybM8m6
From @MedsPatentPool "This unprecedented cooperation from companies that are typically competitors represents a breakthrough in our efforts to level the playing field for access to drugs that will be crucial to controlling and defeating this pandemic" https://t.co/M9he56VswV
In 2019, #NOACs were included in @WHO’s essential medicines list. A year later, @worldheartfed & partners including MPP propose policy recommendations to make these lifesaving innovations #affordable & #available in low-resource settings. 👉Read more in https://t.co/aqTZ5xJRiE https://t.co/JrsRtIrjSA